Department of Psychiatry, University of British Columbia, Vancouver, Canada.
Department of Psychiatry, Université de Montréal, Montreal, Canada.
Can J Psychiatry. 2024 Jul;69(7):493-502. doi: 10.1177/07067437241245331. Epub 2024 Apr 11.
e-Health tools using validated questionnaires to assess outcomes may facilitate measurement-based care for psychiatric disorders. MoodFX was created as a free online symptom tracker to support patients for outcome measurement in their depression treatment. We conducted a pilot randomized evaluation to examine its usability, and clinical utility.
Patients presenting with a major depressive episode (within a major depressive or bipolar disorder) were randomly assigned to receive either MoodFX or a health information website as the intervention and control condition, respectively, with follow-up assessment surveys conducted online at baseline, 8 weeks and 6 months. The primary usability outcomes included the percentage of patients with self-reported use of MoodFX 3 or more times during follow up (indicating minimally adequate usage) and usability measures based on the System Usability Scale (SUS). Secondary clinical outcomes included the Quick Inventory of Depressive Symptomatology, Self-Rated (QIDS-SR) and Patient Health Questionnaire (PHQ-9).
Forty-nine participants were randomized (24 to MoodFX and 25 to the control condition). Of the 23 participants randomized to MoodFX who completed the user survey, 18 (78%) used MoodFX 3 or more times over the 6 months of the study. The mean SUS score of 72.7 (65th-69th percentile) represents good usability. Compared to the control group, the MoodFX group had significantly better improvement on QIDS-SR and PHQ-9 scores, with large effect sizes and higher response rates at 6 months. There were no differences between conditions on other secondary outcomes such as functioning and quality of life.
MoodFX demonstrated good usability and was associated with reduction in depressive symptoms. This pilot study supports the use of digital tools in depression treatment.
使用经过验证的问卷评估结果的电子健康工具可能有助于精神疾病的基于测量的护理。MoodFX 是一个免费的在线症状跟踪器,旨在支持患者进行抑郁症治疗的结果测量。我们进行了一项试点随机评估,以检查其可用性和临床实用性。
出现重度抑郁发作(在重度抑郁或双相情感障碍内)的患者被随机分配接受 MoodFX 或健康信息网站作为干预和对照条件,在基线、8 周和 6 个月时进行在线随访评估调查。主要的可用性结果包括报告在随访期间至少使用 MoodFX 3 次的患者百分比(表明最小的足够使用)和基于系统可用性量表(SUS)的可用性指标。次要临床结果包括快速抑郁症状清单,自我评定(QIDS-SR)和患者健康问卷(PHQ-9)。
49 名参与者被随机分配(24 名至 MoodFX,25 名至对照组)。在完成用户调查的 23 名随机分配至 MoodFX 的参与者中,18 名(78%)在研究的 6 个月内至少使用 MoodFX 3 次。72.7 的平均 SUS 得分(65 到 69 百分位)表示良好的可用性。与对照组相比,MoodFX 组在 QIDS-SR 和 PHQ-9 评分上有显著改善,具有较大的效应量和较高的 6 个月应答率。在其他次要结局(如功能和生活质量)方面,两组之间没有差异。
MoodFX 表现出良好的可用性,并与抑郁症状的减轻相关。这项试点研究支持在抑郁症治疗中使用数字工具。